CourageAS Biotherapeutics is a biotech company established by Couragene and the Foundation for Angelman Syndrome Therapeutics (FAST). CourageAS was co-founded by Dr. Jiangbing Zhou, a Professor of Neurosurgery and Biomedical Engineering, Dr. Amy Liao, a serial entrepreneur, and Dr. Yong-Hui Jiang, Professor, Chief of Medical Genetics at Yale.  CourageAS’ lead indication is Angelman Syndrome, a genetic disorder caused by a loss of nervous system function that affects approximately 1 in 12,000 people. Their STEP (Stimuli-responsive Traceless Engineering Platform) technology has demonstrated great potential to overcome the delivery hurdles for treatment of various diseases, including neurogenetic disorders.